GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (STU:94E) » Definitions » Net-Net Working Capital

Zura Bio (STU:94E) Net-Net Working Capital : €1.84 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Zura Bio's Net-Net Working Capital for the quarter that ended in Mar. 2025 was €1.84.

The industry rank for Zura Bio's Net-Net Working Capital or its related term are showing as below:

STU:94E's Price-to-Net-Net-Working-Capital is ranked better than
94.54% of 879 companies
in the Biotechnology industry
Industry Median: 4.05 vs STU:94E: 0.56

Zura Bio Net-Net Working Capital Historical Data

The historical data trend for Zura Bio's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Net-Net Working Capital Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24
Net-Net Working Capital
- 1.23 2.10

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 2.27 2.10 2.10 1.84

Competitive Comparison of Zura Bio's Net-Net Working Capital

For the Biotechnology subindustry, Zura Bio's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Zura Bio's Price-to-Net-Net-Working-Capital falls into.


;
;

Zura Bio Net-Net Working Capital Calculation

Zura Bio's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(168.556+0.75 * 0+0.5 * 0-18.636
-0-12.61)/65.298
=2.10

Zura Bio's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2025 is calculated as

Net-Net Working Capital(Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(157.776+0.75 * 0+0.5 * 0-19.51
-0-12.214)/68.375
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Zura Bio  (STU:94E) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Zura Bio Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Zura Bio's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio Business Description

Traded in Other Exchanges
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Headlines

No Headlines